![]() ![]() If BESPC is appointed as lead counsel or in a similar capacity in the action, we will provide you with copies of all pleadings in the litigation for your review and approval, circumstances permitting, before they are filed with the court. You will have an obligation to remain knowledgeable about the litigation and participate in decisions concerning the progress of the litigation. If you have any questions about whether information should be retained, please contact us. Relevant documents include any information you have about the Company or your trading in Company stock, no matter how it is recorded or who is keeping it for you. Accordingly, you should preserve all documents that relate to this case until it has concluded or we inform you otherwise. You may also be asked to provide documents concerning your trading in Company stock and may be asked to sit for a deposition. Your Responsibilities as a Representative PlaintiffĪs a representative plaintiff, you will have a duty to represent the interests of similarly situated shareholders, i.e., the “Class,” and to participate in the prosecution of this litigation. The terms under which we will represent you and your responsibilities as a potential representative plaintiff are set forth below. Please provide us with documentation of your trading history in the Company’s stock by emailing a relevant copies of your brokerage statements to If you have any questions or need assistance, please call us at (212) 308-5858. In making this agreement, BESPC is relying upon your representation that you purchased the Company’s shares during the period from to (the “Relevant Period”). ![]() BESPC has conducted an investigation and believes that there is a valid basis to assert claims against the Company and its directors and/or officers for violation of federal or state securities laws. (“BESPC”) to represent you in connection with potential litigation against Silverback Therapeutics (the “Company”) and its directors and officers. This will confirm that you have retained Bragar Eagel & Squire, P.C. If you purchased or otherwise acquired Silverback shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by filling out the form below. Investors have until Januto apply to the Court to be appointed as lead plaintiff in the lawsuit.Īccording to the filed complaint, (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. (“Silverback” or the “Company”) (NASDAQ: SBTX) in the United States District Court for the Western District of Washington on behalf of all persons and entities who purchased or otherwise acquired Silverback securities between Decemand September 10, 2021, both dates inclusive (the “Class Period”) and/or pursuant to the DecemIPO. Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Silverback Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |